• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by enGene Holdings Inc.

    2/23/24 1:32:27 PM ET
    $ENGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ENGN alert in real time by email
    SC 13G 1 tm246984d1_sc13g.htm SC 13G

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Schedule 13G
    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b)

    (Amendment No. ___________)*

      

    enGene Holdings, Inc.

    (Name of Issuer)

     

    Common Shares, no par value

    (Title of Class of Securities)

     

    29286M105

    (CUSIP Number)

     

    February 16, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)

     

    xRule 13d-1(c)

     

    ¨Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    (Continued on following pages)

     

    Page 1 of 10

     

    Exhibit Index on Page 10

     

     

    CUSIP # 29286M105

    Page 2 of 10

     

    1 NAME OF REPORTING PERSONS          Foresite Capital Fund VI, L.P. (“FCF VI”)  
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) x
    3 SEC USE ONLY  
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware
     

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH REPORTING
    PERSON
    WITH
    5 SOLE VOTING POWER
    2,500,000 shares, except that Foresite Capital Management VI, LLC (“FCM VI”), the general partner of FCF VI, may be deemed to have sole power to vote these shares, and James Tananbaum (“Tananbaum”), the managing member of FCM VI, may be deemed to have sole power to vote these shares.
    6 SHARED VOTING POWER
    See response to row 5.
    7 SOLE DISPOSITIVE POWER
    2,500,000 shares, except that FCM VI, the general partner of FCF VI, may be deemed to have sole power to dispose of these shares, and Tananbaum, the managing member of FCM VI, may be deemed to have sole power to dispose of these shares.
    8 SHARED DISPOSITIVE POWER
    See response to row 7.

     

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,500,000
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨ 
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 5.8%1
    12 TYPE OF REPORTING PERSON PN

     

    1 This percentage is calculated based upon 43,197,976 Common Shares outstanding of enGene Holdings Inc. (the “Issuer”), including (a) 23,197,976 Common Shares outstanding as of January 25, 2024, as set forth in the Issuer’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on January 29, 2024 and (b) 20,000,000 Common Shares issued in a private placement on February 16, 2024, as set forth in the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 14, 2024.

     

    CUSIP # 29286M105

    Page 3 of 10

     

    1 NAME OF REPORTING PERSONS          Foresite Capital Management VI, LLC (“FCM VI”)  
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) x
    3 SEC USE ONLY  
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware
     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH REPORTING
    PERSON
    WITH
    5 SOLE VOTING POWER
    2,500,000 shares, all of which are directly owned by FCF VI. FCM VI, the general partner of FCF VI, may be deemed to have sole power to vote these shares, and Tananbaum, the managing member of FCM VI, may be deemed to have sole power to vote these shares.
    6 SHARED VOTING POWER
    See response to row 5.
    7 SOLE DISPOSITIVE POWER
    2,500,000 shares, all of which are directly owned by FCF VI. FCM VI, the general partner of FCF VI, may be deemed to have sole power to dispose of these shares, and Tananbaum, the managing member of FCM VI, may be deemed to have sole power to dispose of these shares.
    8 SHARED DISPOSITIVE POWER
    See response to row 7.

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,500,000
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  ¨
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 5.8%2
    12 TYPE OF REPORTING PERSON OO

     

    2 This percentage is calculated based upon 43,197,976 Common Shares outstanding of the Issuer, including (a) 23,197,976 Common Shares outstanding as of January 25, 2024, as set forth in the Issuer’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on January 29, 2024 and (b) 20,000,000 Common Shares issued in a private placement on February 16, 2024, as set forth in the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 14, 2024.

     

    CUSIP # 29286M105

    Page 4 of 10

     

    1 NAME OF REPORTING PERSONS          James Tananbaum (“Tananbaum”)  
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) x
    3 SEC USE ONLY  
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    United States
     

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH REPORTING
    PERSON
    WITH
    5 SOLE VOTING POWER
    2,500,000 shares, all of which are directly owned by FCF VI. Tananbaum is the managing member of FCM VI, which is the general partner of FCF VI. Tananbaum may be deemed to have sole power to vote these shares.
    6 SHARED VOTING POWER
    See response to row 5.
    7 SOLE DISPOSITIVE POWER
    2,500,000 shares, all of which are directly owned by FCF VI. Tananbaum is the managing member of FCM VI, which is the general partner of FCF VI. Tananbaum may be deemed to have sole power to dispose of these shares.
    8 SHARED DISPOSITIVE POWER
    See response to row 7.

     

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,500,000
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 5.8%3
    12 TYPE OF REPORTING PERSON IN

     

    7 This percentage is calculated based upon 43,197,976 Common Shares outstanding of the Issuer, including (a) 23,197,976 Common Shares outstanding as of January 25, 2024, as set forth in the Issuer’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on January 29, 2024 and (b) 20,000,000 Common Shares issued in a private placement on February 16, 2024, as set forth in the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 14, 2024.

     

    CUSIP # 29286M105

    Page 5 of 10

     

    ITEM 1(A).NAME OF ISSUER

     

    enGene, Inc. (the “Issuer”)

     

    ITEM 1(B).ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES


    4868 Rue Levy, Suite 220

    Saint-Laurent, QC, Canada H2R 2P1

     

    ITEM 2(A).NAME OF PERSONS FILING

    This Schedule is filed by Foresite Capital Fund VI, L.P., a Delaware limited partnership (“FCF VI”), Foresite Capital Management VI, LLC, a Delaware limited liability company (“FCM VI”) and James Tananbaum. The foregoing entities and individuals are collectively referred to as the “Reporting Persons.”

     

    ITEM 2(B).ADDRESS OF PRINCIPAL OFFICE

     

    The address for each of the Reporting Persons is:

     

    c/o Foresite Capital Management

    900 Larkspur Landing Circle, Suite 150
    Larkspur, CA 94939

    ITEM 2(C).CITIZENSHIP


    See Row 4 of cover page for each Reporting Person.

     

    ITEM 2(D).TITLE OF CLASS OF SECURITIES

    Common Shares, no par value

     

    ITEM 2(E)CUSIP NUMBER


    29286M105

     

    ITEM 3.If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

    Not applicable.

     

    ITEM 4.OWNERSHIP

     

    The following information with respect to the ownership of the Common Shares of the Issuer by the persons filing this Statement is provided as of February 16, 2024:

     

    CUSIP # 29286M105

    Page 6 of 10

     

    (a)Amount beneficially owned:

    See Row 9 of cover page for each Reporting Person.

     

    (b)Percent of Class:

    See Row 11 of cover page for each Reporting Person.

     

    (c)Number of shares as to which such person has:

     

    (i)Sole power to vote or to direct the vote:

    See Row 5 of cover page for each Reporting Person.

     

    (ii)Shared power to vote or to direct the vote:

     

    See Row 6 of cover page for each Reporting Person.

     

    (iii)Sole power to dispose or to direct the disposition of:

     

    See Row 7 of cover page for each Reporting Person.

     

    (iv)Shared power to dispose or to direct the disposition of:

    See Row 8 of cover page for each Reporting Person.

     

    ITEM 5.OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

    Not applicable.

     

    ITEM 6.OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.

    Under certain circumstances set forth in the limited partnership agreement of FCF VI and the limited liability company agreement of FCM VI, the partners or members, as the case may be, of each of such entities may be deemed to have the right to receive dividends from, or the proceeds from the sale of, shares of the Issuer directly or indirectly owned by each such entity of which they are a partner or member.

     

    ITEM 7.IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY

    Not applicable.

     

    ITEM 8.IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.

    Not applicable

     

    ITEM 9.NOTICE OF DISSOLUTION OF GROUP.

    Not applicable

     

    CUSIP # 29286M105

    Page 7 of 10

     

    ITEM 10.CERTIFICATION.

    By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

    CUSIP # 29286M105

    Page 8 of 10

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 23, 2024

     

      FORESITE CAPITAL FUND VI, L.P.
         
      By: FORESITE CAPITAL MANAGEMENT VI, LLC
      Its: General Partner
         
      By: /s/ James Tananbaum
      Name: James Tananbaum
      Title: Managing Member
         
      FORESITE CAPITAL MANAGEMENT VI, LLC
         
      By: /s/ James Tananbaum
      Name: James Tananbaum
      Title: Managing Member
         
      JAMES TANANBAUM
         
      By: /s/ James Tananbaum
      Name: James Tananbaum

      

    CUSIP # 29286M105

    Page 9 of 10

     

    EXHIBIT INDEX

     

      Found on
    Sequentially
    Exhibit Numbered Page
       
    Exhibit A:  Agreement of Joint Filing 10

     

    CUSIP # 29286M105

    Page 10 of 10

     

    exhibit A

     

    Agreement of Joint Filing

     

    The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Common Shares of the Issuer shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13G.

     

    Date: February 23, 2024

     

      FORESITE CAPITAL FUND VI, L.P.
         
      By: FORESITE CAPITAL MANAGEMENT VI, LLC
      Its: General Partner
         
      By: /s/ James Tananbaum
      Name: James Tananbaum
      Title: Managing Member
         
      FORESITE CAPITAL MANAGEMENT VI, LLC
         
      By: /s/ James Tananbaum
      Name: James Tananbaum
      Title: Managing Member
         
      JAMES TANANBAUM
         
      By: /s/ James Tananbaum
      Name: James Tananbaum

     

     

    Get the next $ENGN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ENGN

    DatePrice TargetRatingAnalyst
    2/18/2025$26.00Overweight
    Piper Sandler
    2/14/2025$34.00 → $7.00Buy → Neutral
    UBS
    12/23/2024$25.00Buy
    H.C. Wainwright
    11/27/2024$23.00Outperform
    Raymond James
    11/18/2024$18.00Mkt Outperform
    JMP Securities
    8/28/2024$30.00Outperform
    Oppenheimer
    4/22/2024$30.00Overweight
    Wells Fargo
    4/15/2024$34.00Buy
    Guggenheim
    More analyst ratings

    $ENGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by enGene Holdings Inc.

      SC 13G/A - enGene Holdings Inc. (0001980845) (Subject)

      11/14/24 5:48:15 PM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by enGene Holdings Inc.

      SC 13G/A - enGene Holdings Inc. (0001980845) (Subject)

      11/14/24 5:05:21 PM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by enGene Holdings Inc.

      SC 13G/A - enGene Holdings Inc. (0001980845) (Subject)

      11/14/24 7:53:57 AM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ENGN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • enGene to Participate in Upcoming Investor Conferences

      enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage, non-viral genetic medicines company, today announced that management will present at upcoming investor conferences in May 2025. Details of the conferences are below: Conference: 2025 Bloom Burton & Co. Healthcare Investor Conference Date: Monday, May 5, 2025 Time: 2:30 p.m. ET Format: Corporate Presentation Conference: The Citizens Life Sciences Conference Date: Wednesday, May 7, 2025 Time: 11:30 a.m. ET Format: Fireside Chat A live webcast of these presentations can be accessed under the "Investors" section of the enGene website at www.engene.com and will be archived there for 90 days. About enGene enGene is a clinical-stage biotec

      4/28/25 8:00:00 AM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

      enGene Holdings Inc. (NASDAQ:ENGN, "enGene" or the "Company")), a clinical-stage, non-viral genetic medicines company, today reported the grant of inducement equity awards to seven newly-hired employees, with a grant date of April 2, 2025. The inducement awards consist of a non-qualified stock options to purchase an aggregate 144,650 of the Company's common shares. The options each have an exercise price of $4.44 per share, which is equal to the closing price of the Company's common shares on April 2, 2025, the date of grant. Each stock option has a 10-year term and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the employee's employment

      4/4/25 8:00:00 AM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • enGene to Present at the Stifel 2025 Virtual Targeted Oncology Forum

      enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage, non-viral genetic medicines company, today announced that Ron Cooper, Chief Executive Officer, will present at the Stifel 2025 Virtual Targeted Oncology Forum, on Tuesday, April 8, 2025, at 4:00 p.m. ET. A live webcast of the presentation can be accessed under the "Investors" section of the enGene website at www.engene.com and will be archived there for 90 days. About enGene enGene is a clinical-stage biotechnology company mainstreaming genetic medicines through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs. enGene's lead program is det

      4/1/25 8:00:00 AM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ENGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Forbion Growth Opportunities Fund I Cooperatief U.A. bought $4,999,993 worth of shares (561,797 units at $8.90) (SEC Form 4)

      4 - enGene Holdings Inc. (0001980845) (Issuer)

      11/1/24 4:15:08 PM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Forbion Growth Opportunities Fund I Cooperatief U.A. bought $3,012,674 worth of shares (470,633 units at $6.40) (SEC Form 4)

      4 - enGene Holdings Inc. (0001980845) (Issuer)

      10/18/24 4:15:05 PM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Executive Officer Cooper Ronald Harold Wilfred bought $57,000 worth of shares (10,000 units at $5.70) (SEC Form 4)

      4 - enGene Holdings Inc. (0001980845) (Issuer)

      10/1/24 8:02:44 AM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ENGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Medical Officer Pruthi Raj Som

      4 - enGene Holdings Inc. (0001980845) (Issuer)

      1/31/25 4:46:11 PM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Strategy & Ops. Ofc Nichols Alexander Julian

      4 - enGene Holdings Inc. (0001980845) (Issuer)

      1/31/25 4:44:27 PM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Legal Ofc. and Corp Secy Giguere Lee

      4 - enGene Holdings Inc. (0001980845) (Issuer)

      1/31/25 4:42:31 PM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ENGN
    Leadership Updates

    Live Leadership Updates

    See more
    • enGene Appoints Joan Connolly as Chief Technology Officer and Anthony Cheung, Ph.D., as Chief Scientific Officer

      enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as detalimogene, and previously EG-70) is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis), today announced the appointment of Joan Connolly as Chief Technology Officer (CTO) and member of the corporate leadership team. In addition, enGene Co-Founder and former CTO, Anthony Cheung, Ph.D., will transition to the role of Chief Scientific Officer, succeeding James Sullivan, MSc, Ph.D. Ms. Connolly's career spans

      10/21/24 8:45:00 AM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • enGene Announces Appointment of Ron Cooper as Chief Executive Officer

      Ron Cooper succeeds Jason Hanson as Chief Executive Officer and Director Company also announces Dr. Raj Pruthi's promotion to Chief Medical Officer enGene Holdings Inc. (NASDAQ:ENGN, "enGene" or the "Company"))), a clinical-stage genetic medicines company whose non-viral, intravesical lead product candidate, EG-70, is in a pivotal study for BCG-unresponsive high-risk Non-Muscle Invasive Bladder Cancer (NMIBC), today announced that Ron Cooper has joined the Company as Chief Executive Officer and member of the Board of Directors, effective July 22, 2024. This transition follows a previously announced succession plan for Jason Hanson, who will remain in service to the Company as a strategi

      7/24/24 6:30:00 AM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors

      enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced the election of Paul Hastings and Wouter Joustra as new members of its Board of Directors at the Company's 2024 annual meeting of shareholders. Shareholders also reelected incumbent director Lota Zoth. Each will serve a three-year term expiring at the 2027 annual meeting of shareholders. enGene's Board is now comprised of seven members including Richard Glickman (Chairman), Gerald Brunk, Jasper Bos, and Jason Hanson. "We are pleased to welcome Paul and Wouter to our Board of

      5/15/24 4:05:00 PM ET
      $ENGN
      $NAMS
      $NKTX
      $PCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $ENGN
    Financials

    Live finance-specific insights

    See more
    • enGene Reports First Quarter 2025 Financial Results and Provides Business Update

      Additional preliminary data from ongoing LEGEND study of detalimogene in BCG-unresponsive NMIBC with CIS, including pivotal cohort, anticipated in 2H 2025 Biologics License Application (BLA) filing planned for mid-2026 remains on track Cash and marketable securities of $272.8 million expected to provide runway into 2027 enGene Holdings Inc. (NASDAQ:ENGN, or "enGene" or the "Company")), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the first quarter ended January 31, 2025, and provided a business update. "With the expansion of LEGEND study sites into Europe and Asia, enrollment in our pivotal cohort continues to track in-line with our pl

      3/10/25 4:05:00 PM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • enGene Reports Full Year 2024 Financial Results and Provides a Business Update

      BLA filing for detalimogene in BCG-unresponsive NMIBC with CIS on track for mid-2026 All cohorts of the Phase 2 LEGEND study now recruiting under updated protocol Additional preliminary data from pivotal cohort anticipated in 2H 2025 Cash, cash equivalents and marketable securities of $297.9 million provide runway into 2027 enGene Holdings Inc. (NASDAQ:ENGN, or "enGene" or the "Company")), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid, (also known as detalimogene, and previously EG-70), is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder

      12/19/24 4:05:00 PM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Detalimogene Demonstrates 71% Complete Response Rate at Any Time in Preliminary Analysis of LEGEND Pivotal Cohort

      Data from pivotal cohort demonstrate compelling clinical activity, consistent with Phase 1 results Favorable tolerability profile with no drug-related discontinuations Detalimogene's profile to date supports its potential as a foundational therapy for NMIBC enGene to host a conference call to discuss preliminary data today at 8:00 a.m. ET enGene Holdings Inc. (NASDAQ:ENGN), is a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as detalimogene, and previously EG-70) is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with

      9/26/24 6:30:00 AM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ENGN
    SEC Filings

    See more
    • SEC Form DEF 14A filed by enGene Holdings Inc.

      DEF 14A - enGene Holdings Inc. (0001980845) (Filer)

      5/9/25 4:05:24 PM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 filed by enGene Holdings Inc.

      S-8 - enGene Holdings Inc. (0001980845) (Filer)

      3/10/25 4:27:39 PM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by enGene Holdings Inc.

      10-Q - enGene Holdings Inc. (0001980845) (Filer)

      3/10/25 4:10:30 PM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ENGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Piper Sandler initiated coverage on enGene Holdings with a new price target

      Piper Sandler initiated coverage of enGene Holdings with a rating of Overweight and set a new price target of $26.00

      2/18/25 7:08:31 AM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • enGene Holdings downgraded by UBS with a new price target

      UBS downgraded enGene Holdings from Buy to Neutral and set a new price target of $7.00 from $34.00 previously

      2/14/25 8:16:16 AM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • H.C. Wainwright initiated coverage on enGene Holdings with a new price target

      H.C. Wainwright initiated coverage of enGene Holdings with a rating of Buy and set a new price target of $25.00

      12/23/24 7:22:45 AM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care